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Background: The effectiveness of sugammadex in reversing rocuronium-induced neuromuscular blockade (NMB) in
the presence of drugs that may potentiate NMB remains to be fully established. The aim of this post-hoc analysis of
data from a Phase III clinical trial (VISTA; NCT00298831) was to investigate the impact of antibiotics on recovery from
rocuronium-induced NMB after administration of sugammadex for reversal, and compared the neuromuscular
recovery in patients who received antibiotics preoperatively with those who did not.
Methods: A Phase III, multicenter, open-label study designed to reflect potential use of sugammadex in clinical
practice was conducted at 19 sites. Data obtained from patients who received antibiotics were compared with the
cohort of patients who underwent the same protocol without antibiotics. Each subject received rocuronium
0.6 mg/kg for muscle relaxation, after which tracheal intubation was performed; patients were also permitted to
receive maintenance doses of rocuronium 0.15 mg/kg to maintain the desired level of NMB throughout the
operation, as required.. At least 15 min after the last rocuronium dose, patients received sugammadex 4.0 mg/kg
for reversal. Neuromuscular monitoring was continued until a train-of-four (TOF) ratio of ≥0.9 was achieved or the
anesthetic was discontinued.
Results: The presence of antibiotics prior to the administration of sugammadex did not affect the recovery time
from rocuronium-induced NMB when sugammadex 4.0 mg/kg was administered at least 15 min after the last dose
of rocuronium. In the presence of antibiotics, the geometric mean (95% CI) time from administration of sugammadex
4.0 mg/kg to recovery of the TOF ratio to ≥0.9 was 1.6 (1.4–1.9) min (range: 0.7–10.5 min), compared with 2.0 (1.8–2.3)
min (range: 0.7–22.3 min) for patients who did not receive antibiotics.
Conclusions: These findings suggest that prophylactic antibiotic use is unlikely to have a major impact on the
recovery time from rocuronium-induced NMB with sugammadex reversal.
Trial registration: ClinicalTrials.gov Identifier: NCT00298831.
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Sugammadex is a modified γ-cyclodextrin that effectively
reverses moderate and deep neuromuscular blockade
(NMB) induced by the non-depolarizing muscle relax-
ants rocuronium and vecuronium [1-5]. However, the ef-
fectiveness of sugammadex in reversing rocuronium in
the presence of drugs that potentiate NMB remains to
be fully established. Certain classes of drugs are known
to potentiate the activity of the neuromuscular blocking
agents (NMBAs) if used in the perioperative setting* Correspondence: hudsonme@anes.upmc.edu
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unless otherwise stated.[6-11], including several antibiotics [6,9-11]. Further-
more, the presence of certain antibiotics may limit the
ability of traditional reversal agents such as neostigmine
to reverse NMB [6,12]. In cases where neostigmine is
found to be ineffective, this may be a consequence of the
antibiotic potentiating NMB through inhibition of acetyl-
choline release from the nerve terminal. A reduced con-
centration of acetylcholine would reduce competition for
the NMBA to bind to the nicotinic acetylcholine receptor ,
thereby potentiating the NMB. However, since neo-
stigmine works by reducing enzymatic breakdown of
acetylcholine in the neuromuscular junction to increase
the concentration of acetylcholine, thereby shifting thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hudson et al. BMC Anesthesiology 2014, 14:69 Page 2 of 5
http://www.biomedcentral.com/1471-2253/14/69competition between acetylcholine and the NMBA for the
binding site in favor of acetylcholine, a reduced availability
of acetylcholine may subsequently limit the effectiveness
of neostigmine.
Since sugammadex works by a different mechanism to
neostigmine, forming 1:1 complexes with rocuronium or
vecuronium, encapsulating the NMBA, resulting in its
inactivation [13], it is not anticipated that antibiotics will
impact on its ability to reverse rocuronium- or vecuronium-
induced NMB. In the current study, we investigate this
further.
Since in previous studies conducted to assess the safety
and efficacy of sugammadex, patients who received an-
tibiotics perioperatively were excluded, a post-hoc ana-
lysis of data from a Phase III clinical trial (study ID:
NCT00298831) was performed to assess the effects of
antibiotic administration on sugammadex properties in
reversing NMB produced by rocuronium. In an attempt
to reflect clinical practice in this Phase III study, there
were no restrictions on anesthetic regimen or procedure,
with only limited restrictions on concomitant medications.
However, medications in a dose and/or at a time point
known to interfere with the action of non-depolarizing
NMBAs, including antibiotics, were listed among the ex-
clusion criteria. Despite this, a relatively large number of
patients received prophylactic antibiotics (per the routine
practice for several study sites) in deviation from the study
protocol, thereby allowing comparison with those patients
who did not receive antibiotics.
Methods
The Phase III (VISTA) study was a multicenter, open-
label study conducted at 19 sites in the USA between
October 2005 and May 2006, data from which have been
published previously [1], and was designed to reflect a
potential use of sugammadex in clinical practice. This
study was conducted in accordance with principles of
Good Clinical Practice and was approved by the appro-
priate institutional review boards and regulatory agen-
cies (Additional file 1). Written informed consent was
obtained from all patients. Antibiotic use was listed
under the exclusion criteria, as antibiotics may interfere
with the action of non-depolarizing NMBAs. In the
current post-hoc analysis to establish the impact of anti-
biotic administration on the ability of sugammadex to re-
verse the muscle relaxant property of rocuronium, data
obtained from sugammadex-treated patients who received
antibiotics (deviating from the study protocol) were com-
pared with the cohort of patients who underwent the
same protocol without antibiotics.
As previously described [1], inclusion criteria included
age between 18–70 years with American Society of
Anesthesiologists physical status I–III and scheduled
to undergo elective surgery in the supine position undergeneral anesthesia requiring muscle relaxation. Non-
standardized anesthesia was induced and maintained with
an intravenous opioid, an anesthetic, and other agent(s)
according to the clinical need of each subject. Anesthesia
practices not specified in the protocol were to be consist-
ent with the routine practices at the study site. Most pa-
tients (99%) included in the study received propofol and/
or an opioid for induction of anesthesia; the remaining
patients received either sevoflurane or desflurane. The
most common anesthetics used for the maintenance of
anesthesia were sevoflurane and desflurane, although some
patients received either propofol or isoflurane.
Neuromuscular monitoring was performed continuously
at the adductor pollicis muscle with acceleromyography
(TOF-Watch® SX; Organon Ireland Ltd, a division of
Merck and Co., Dublin, Ireland). After calibration of the
TOF-Watch, each subject received rocuronium 0.6 mg/kg
for muscle relaxation, after which tracheal intubation was
performed. Patients were permitted to receive mainten-
ance doses of rocuronium 0.15 mg/kg upon reappearance
of the second twitch of the train-of-four (TOF) to main-
tain NMB throughout the operation as required. At least
15 min after the last dose of rocuronium, patients received
sugammadex 4.0 mg/kg for reversal. Neuromuscular mon-
itoring was continued until a TOF ratio of ≥0.9 was
achieved or the anesthetic was discontinued. The primary
efficacy variable was the time from the start of sugamma-
dex administration until recovery of the TOF ratio to ≥0.9.
Data analysis
Recovery times were summarized by geometric mean
(95% confidence interval [CI]) times, as these times were
expected to follow a skewed distribution and the geo-
metric mean is robust against data distributed in this
way [14]. Data were also summarized as number and
percentage of patients recovering to a TOF ratio of ≥0.9
within each minute time interval after sugammadex ad-
ministration. An analysis of variance (ANOVA) model
was used to investigate the effect of depth of NMB at the
time of sugammadex administration (number of twitches
to TOF stimulation: 0 or ≥1) and use of antibiotics on
the (log) time to recovery to a TOF ratio of ≥0.9. This
ANOVA model also included study center.
Safety was assessed by adverse events (AEs, coded by
Medical Dictionary for Regulatory Activities version 9.1),
laboratory variables, vital signs, and clinical signs of neuro-
muscular recovery.
Results
Of the 224 patients enrolled in the original trial, only pa-
tients who received sugammadex were included in the
current analysis (n = 197). Of these 197 patients, 64 re-
ceived an antibiotic known to interfere with NMBAs before
recording any efficacy parameters, including kanamycin
Table 1 Baseline demographics of patients receiving
sugammadex in the overall study
Antibiotics
(n = 64)
No antibiotics
(n = 133)
Age, years, mean (SD) 57 (13) 51 (16)
Weight, kg, mean (SD) 87 (20) 82 (20)
Height, cm, mean (SD) 172 (9) 169 (10)
Gender, n (%)
Male 39 (61) 55 (41)
Race, n (%)
Asian 1 (2) 4 (3)
Black, of African heritage 5 (8) 13 (10)
White/Caucasian 58 (91) 114 (86)
Other 0 (0) 2 (2)
ASA class, n (%)
I 4 (6) 23 (17)
II 51 (80) 84 (63)
III 9 (14) 26 (20)
ASA: American Society of Anesthesiologists; SD: standard deviation.
Table 3 Summary of times to recovery of the TOF ratio to
0.9 following administration of sugammadex ≥15 min
after the last dose of rocuronium (analyzed by antibiotic
administration and NMB depth for patients with data
available for the number of twitches at the start of
sugammadex administration)
Antibiotics No. of
twitches
n Geometric mean
recovery time (min)
95% confidence
interval
No 0 60 2.4 2.0–2.7
No ≥1 51 1.6 1.4–1.9
No 111† 2.0 1.8–2.2
Yes 0 24 2.2 1.7–2.8
Yes ≥1 33 1.3 1.2–1.5
Yes 57† 1.6 1.4–1.9
NMB: neuromuscular blockade; TOF: train-of-four.
†Nine patients (three patients who received antibiotics and six who did not) had
data available for recovery to a TOF ratio of ≥0.9, but no data regarding the
depth of NMB (number of twitches) at the time of sugammadex administration.
The text in bold indicates the sub-totals of antibiotics or no antibiotics,
irrespective of the NMB depth.
Table 4 Cumulative number and percentage of patients
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mycin (n = 6) and bacitracin (n = 3). Table 1 presents the
demographic data for the two groups. The route of ad-
ministration of antibiotics was intravenous (n = 34); oral
(n = 1); intra-articular (n = 1) or in the abdominal wash
(n = 28) (Table 2).
Four patients who received antibiotics and 16 who did
not receive antibiotics were excluded from the current
efficacy analysis because they did not have data avail-
able for a time to the TOF ratio of 0.9 (data missing
or deemed unreliable by a central independent adjudication
committee; reasons for missing or unreliable data included
technical difficulties with the monitoring equipment and a
clinical need to discontinue monitoring prior to reaching a
TOF ratio of 0.9). In the presence of antibiotics (n = 60),
the geometric mean (95% CI) time from administration
of sugammadex 4.0 mg/kg to recovery of the TOF ra-
tio to ≥0.9 was 1.6 (1.4–1.9) min (range: 0.7–10.5 min),
compared with 2.0 (1.8–2.3) min (range: 0.7–22.3 min) for
patients who did not receive antibiotics (n = 117).Table 2 Frequency of antibiotics by route of administration
Route of administration
Intravenous Oral Intra-articular Abdominal
wash
Total
Kanamycin 0 0 0 26 26
Gentamycin 19 1 0 0 20
Vancomycin 9 0 0 0 9
Clindamycin 6 0 0 0 6
Bacitracin 0 0 1 2 3
34 1 1 28 64In the original study, which was designed at the time
to reflect a potential use in clinical practice, reversal
at ≥15 min after the last dose of rocuronium resulted in
a variability in the depth of NMB at the time of reversal
[1]. As a consequence, while some patients in the study
may have received sugammadex 4.0 mg/kg at an appro-
priate level of NMB, some have received sugammadex at
a deeper NMB than recommended for this dose. Recov-
ery times by antibiotic administration and NMB depth
for patients with data available for the number of
twitches at the start of sugammadex administration are
shown in Table 3; analyses of the recovery times showed
a difference in recovery between patients with zero twitches
and those with one or more twitches (P < 0.0001), but no
statistically significant difference was observed between
patients who received antibiotics and those who did not,
P = 0.30. The estimated treatment effect (adjusted for cen-
ter effects) for the ratio of the geometric means for pa-
tients who received no antibiotics and those who did was
1.11 (95% CI 0.91–1.35), while for patients who had zerowho recovered after sugammadex administration to TOF
ratio ≥0.9, by receiving antibiotics or not (patients with
available recovery data)
Time to TOF
ratio ≥0.9
Antibiotics (n = 60) No antibiotics (n = 117)
n % n %
≤1 min 9 15.0 11 9.4
≤2 min 44 73.3 63 53.9
≤3 min 51 85.0 94 80.3
≤4 min 55 91.7 103 88.0
≤5 min 59 98.3 110 94.0
TOF: train-of-four.
Figure 1 Cumulative percentage of patients who recovered, after sugammadex administration, to TOF ratio ≥0.9, by receiving
antibiotics or not (patients with available recovery data).
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geometric means was 1.46 (95% CI 1.23–1.73).
Table 4 presents, per minute, the cumulative number
and percentage of patients who recovered after sugam-
madex administration to TOF ratio ≥0.9. For one patient
(1.7%) who received antibiotics, the time from sugam-
madex administration to recovery of the TOF ratio ≥0.9
took more than 5 min (10.5 min), compared with seven
patients (6.0%) who did not receive antibiotics (Table 4;
Figure 1). For the patient in the antiobiotic group with
the relatively long recovery time to a TOF ratio of ≥0.9
(10.5 min), there were zero twitches in response to TOF
stimulation at the time of sugammadex administration, po-
tentially meaning that the depth of NMB was deeper than
recommended for the dose of sugammadex used, which
may help to explain the slower recovery observed. Simi-
larly, three of the patients with recovery times >5 min in
the group that did not receive antibiotics had zero twitches
at the time of sugammadex administration (recovery times
were 6.9, 6.9 and 22.3 min), while one patient had no data
available for the depth of NMB (recovery time 10.7 min);
the remaining three patients had ≥1 twitches (recovery
times 5.2, 6.4 and 8.5 min).
Overall, the majority of patients who received sugam-
madex reported at least one AE: 96.9% of patients who
received an antibiotic and 97.7% of patients who did not
receive an antibiotic. Of patients who received antibiotics,
four (6.3%) experienced AEs considered possibly related to
sugammadex: procedural hypertension (n = 1), procedural
hypotension (n = 1), wheezing (n = 1) and increased blood
creatinine phosphokinase (n = 1); 18 (13.5%) patients who
did not receive antibiotics reported an AE considered by
the investigator to be possibly related to sugammadex, with
the most common being hematuria (n = 4). There wereeight serious AEs in the study as a whole, two in patients
receiving an antibiotic and six in patients not receiving an
antibiotic; none of these serious AEs were considered re-
lated to sugammadex.
Discussion and Conclusions
In the current post-hoc analysis, the presence of antibi-
otics prior to the administration of sugammadex 4.0 mg/kg
did not affect the ability of sugammadex to reverse the
NMB produced by rocuronium when administered at least
15 min after the last dose of rocuronium, with no sig-
nificant difference observed in recovery time between pa-
tients who received preoperative antibiotics compared
with a cohort of patients who underwent the same proto-
col without antibiotic administration. While it cannot be
concluded from these analyses that antibiotics have no
effect on sugammadex reversal of rocuronium-induced
NMB, the data presented suggest that prophylactic anti-
biotic use is unlikely to have a major impact on recovery
time.
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